Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

3 CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
Yuwen Zhu and Lieping Chen
See related article, p. 44

6 Targeting Metabolic Scavenging in Pancreatic Cancer
Costas A. Lyssiotis and Lewis C. Cantley
See related article, p. 120

CCR Perspectives in Drug Approval

9 Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

CCR Drug Updates

15 Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer
Ian Krop and Eric P. Winer

Molecular Pathways

21 Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer—Mechanisms and Potential Therapeutic Insights
Xiaofeng Wang, Jeffrey R. Haswell, and Charles W.M. Roberts

28 Molecular Pathways: Sterols and Receptor Signaling in Cancer
Linara Gabitova, Andrey Gorin, and Igor Astsaturov

Review

35 Noncoding RNAs in Prostate Cancer: The Long and the Short of It
Eva M. Bolton, Alexandra V. Tuzova, Anna L. Walsh, Thomas Lynch, and Antoinette S. Perry

HUMAN CANCER BIOLOGY

44 CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Qunrui Ye, De-Gang Song, Mathilde Poussin, Tori Yamamoto, Andrew Best, Chunsheng Li, George Coukos, and Daniel J. Powell Jr.
See related article, p. 3

56 αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain

68 A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

76 HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer
Vikas Sebdev, Ahmed Katsha, Janet Arras, Dunfa Peng, Mohammed Soufflo, Jeffrey Ecsedy, Alexander Zaika, Abbes Belkhiri, and Wael El-Rifai

87 Discrete Molecular Classes of Ovarian Cancer Suggestive of Unique Mechanisms of Transformation and Metastases
Nilesh L. Gardi, Tejaswini U. Deshpande, Swapnail C. Kamble, Sagar R. Badhe, and Sharmila A. Bapat

100 Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo
Olga Dakhova, David Rowley, and Michael Ittmann

CANCER THERAPY: PRECLINICAL

110 The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
Thomas J. Hayman, Amy Wahba, Barbara H. Rath, Heesyoung Bae, Tamalee Kranp, Uma T. Shankavaram, Kevin Camphausen, and Philip J. Tofilon
120  Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Claudia C.S. Chini, Ana M. Gonzalez Guerrico, Veronica Nin, Juliana Camacho-Pereira, Carlos Escande, Maria Thereza Barbosa, and Eduardo N. Chini
See related article, p. 6

131  Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Serena K. Perna, Daria Pagliara, Aruna Mahendravada, Hao Liu, Malcolm K. Brenner, Barbara Savoldo, and Gianpietro Dotti

140  Transient Activation of Hedgehog Pathway Rescued Irradiation-Induced Hyposalivation by Preserving Salivary Stem/Progenitor Cells and Parasympathetic Innervation
Bo Hai, Lizheng Qin, Zhenhua Yang, Qingguo Zhao, Lei Shangguan, Xinyu Ti, Yanqi Zhao, Sangroh Kim, Dharanipathy Rangaraj, and Fei Liu

151  Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation
Xianping Shi, Xin Chen, Xiaofen Li, Xiaoying Lan, Chong Zhao, Shoutting Liu, Hongbiao Huang, Ningsning Liu, Siyan Liao, Wenbin Song, Ping Zhou, Shunqing Wang, Li Xu, Xuejun Wang, Q. Ping Dou, and Jinbao Liu

164  AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Philip D. Dunne, Darragh G. McArt, Jaime K. Blaney, Murugan Kalimutho, Samanda Greer, Tingting Wang, Supriya Srivastava, Chee Wei Ong, Ken Arthur, Maurice Loughrey, Kearsa Redmond, Daniel B. Longley, Manuel Salto-Tellez, Patrick G. Johnston, and Sandra Van Schaeybroeck

176  Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleosome Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
Vijaya L. Damaraju, Tara Scriver, Delores Mowles, Michelle Kuzma, Anderson J. Ryan, Carol E. Cass, and Michael B. Sawyer

187  Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Ji Liang, Yuji Piao, Lindsay Holmes, Gregory N. Fuller, Verlene Henry, Ningyi Tiao, and John F. de Groot

199  Direct Inhibition of Retinoblastoma Phosphorylation by Nimibolide Causes Cell-Cycle Arrest and Suppresses Glioblastoma Growth
Swagata Karkare, Rishi Raj Chhipa, Jane Anderson, Xiaolu Liu, Heather Henry, Anjelika Gasilina, Nicholas Nassar, Jayanta Roychoudhury, Jason P Clark, Ashish Kumar, Giovanni M. Pauletli, Pradip K. Ghosh, and Biplob Dasgupta

CANCER THERAPY: CLINICAL

213  A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Vincent Ribrag, Jehan Dupuis, Herve Tilly, Franck Morschhauser, Fabrice Laine, Roch Houot, Corinne Haioun, Christiane Copie, Andrea Varga, John Lambert, Laurence Hatteville, Samira Ziti-Ljaic, Anne Caron, Sandrine Payrard, and Bertrand Coiffier

221  Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Trine Zeeberg Iversen, Lotte Engel-Norregaard, Eva Ellebaek, Rikke Andersen, Stine Klaer Larsen, Jon Bjørn, Claus Zeyher, Cécile Gouttefangeas, Birthe Moerk Thomsen, Bente Holm, Per thor Straten, Anders Mellemgaard, Mads Hald Andersen, and Inge Marie Svane

233  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

246  Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Serge Koscienly, Antonin Levy, Christophe Massard, Rastislav Balbeda, Brian Bot, Carlos Gomez-Roca, Clarisse Dromain, Samy Ammar, and Jean-Charles Soria
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Kimberley Jones, Jamie P. Nourse, Colm Keane, Atul Bhatnagar, and Maher K. Gandhi

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Justin Guinney, Charles Ferté, Jonathan Dry, Robert McEwen, Gilles Manceau, KJ Kao, Kai-Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Ducreux, Jean-Charles Soria, Stephen Friend, Jonathan Derry, and Pierre Laurent-Puig

ABOUT THE COVER
The cover shows immunofluorescent labeling of the blood-brain barrier marker GLUT-1 (red) in cultured human brain microvascular endothelial cells. Nuclei (blue) were stained with DAPI. For details, see the article by Malin and colleagues on page 56 of this issue.
Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.